Examining B12 Deficiency Associated With C677T Mutation on MTHFR Gene in Terms of Commonness and Endothelial Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the commonness of the C677T mutation in the MTHFR gene in subjects with B12 deficiency. Also, we'd like to investigate the effect of B12 deficiency combined with the C677T mutation on endothelial function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption

NCT00235573

Disorder of Vitamin B12

COMPLETED NA

Vitamin B12 Biomarker Responses to Supplementation

NCT04731948

Healthy

COMPLETED NA

Effect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status

NCT05785585

Vitamin B12 Nutritional Deficiency

RECRUITING NA

A Study to See if a Combination of Vitamins That is Injected Into a Muscle is as Good and Safe as a Vitamin That is Taken by Mouth

NCT07029698

Vitamin B12 Deficiency

RECRUITING PHASE4

Effect of Betaine, Serine and Folic Acid on Vascular Function in Healthy Volunteers

NCT00126347

Healthy Cardiovascular Diseases

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

we showed that patiebts with B12 deficiency have higher than expected frequency of MTHFR mutation and patients with both abnormalities havean abnormal endothelial function

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

B12 Deficiency Combined With C677T Mutation on MTHFR Gene

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

B

The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .

Group Type NO_INTERVENTION

No interventions assigned to this group

A

The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)

Group Type EXPERIMENTAL

Vitamin B12 + Folic Acid

Intervention Type DIETARY_SUPPLEMENT

Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin B12 + Folic Acid

Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vitamin B12, 1 mg, by Solgar Folic acid, 5 mg, by Rakah

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. adult males and females of the broad population aged 20-60
2. with no symptomatic heart disease/condition
3. with Vitamin B12 levels of 150 pmol or less
4. which have not received Vitamin B12 supplement treatment before

Exclusion Criteria

1. Adults suffering from a known heart disease/condition
2. any disease the investigator might find as interfering with the process of the experiment
3. tumor-oriented diseases

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No